Abstract
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the
efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC)
chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating
rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
